Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Walnut and pecan allergens are a group of highly cross-reactive proteins from the Juglandaceae family, primarily comprising seed storage proteins such as 2S albumins (Jug r 1, Car i 1), 7S globulins (Jug r 2, Jug r 6, Car i 2), and 11S globulins (Jug r 4, Car i 4) (nih.gov, researchgate.net). These proteins share significant sequence identity and structural homology, leading to high rates of co-sensitization and clinical cross-reactivity; for instance, Jug r 1 and Car i 1 share approximately 88% sequence identity (nih.gov). Sensitization to these allergens is a major cause of severe food-induced allergic reactions, including life-threatening anaphylaxis, and is typically persistent throughout life (londonallergyconsultants.co.uk, usda.gov). In clinical practice, these allergens serve as targets for component-resolved diagnosis (CRD) to distinguish between primary sensitization and cross-reactivity with other nuts or pollens (thermofisher.com, nih.gov). They are also the primary targets for therapeutic interventions such as oral immunotherapy (OIT) and investigational DNA vaccines, which aim to induce desensitization by shifting the immune response from a Th2-mediated allergic profile to a Th1-mediated tolerant profile (londonallergyconsultants.co.uk, usda.gov). Management of patients sensitized to these allergens requires strict dietary avoidance and the availability of emergency epinephrine (londonallergyconsultants.co.uk, usda.gov).
Immunotherapy-mediated desensitization, IgE-mediated immune activation, Th2 to Th1 immune response shifting
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Walnut and pecan cross-reactive allergens.